Skip to content

Medically-Graded Honey Supplementation Formula To Preterm Infants

Randomized Controlled Trial on Medically-Graded Honey Supplementation Formula (As a Prebiotic) To Preterm Infants

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02679183
Acronym
Honey
Enrollment
40
Registered
2016-02-10
Start date
2011-01-31
Completion date
2014-03-31
Last updated
2016-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Honey, Intestinal Microbiota, Prebiotics, Premature Infants

Brief summary

Honey is a natural product that contains multiple nutrients; it is composed of fructose, glucose and fructooligosaccharides that can potentially serve prebiotic functions. It also contains more than 180 substances including amino acids, vitamins, minerals and enzymes. Investigators hypothesized that supplementation of enteral feeds with honey would produce a bifidogenic effect and stimulate the immune response in preterm infants. Investigators randomly assigned subjects to 4 groups receiving 0, 5, 10 and 15 grams of honey daily for 2 weeks and measured their effect on stool colonization, systemic immune parameters and anthropometric measurements.

Interventions

DIETARY_SUPPLEMENTMedically-Graded Honey

Honey added to the baby formula once a day for 2 weeks.

OTHERPremature Milk Formula

Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Days to 3 Weeks
Healthy volunteers
No

Inclusion criteria

* preterm infants with gestational age ≤ 34 weeks * postnatal age \> 3 days * no previous enteral feeding, and * parental wish to use milk formula with no intention to use breast milk or breastfeed.

Exclusion criteria

* infants with major chromosomal abnormalities * Infant with major congenital anomalies of the cardiovascular, pulmonary or central nervous system; including neuromuscular disorders and neural tube defects * infants with intestinal atresia, tracheoesophageal fistulas, omphalocele, gastroschisis, and other major congenital GI anomalies, and * infants with sepsis, either before or during enrollment

Design outcomes

Primary

MeasureTime frameDescription
The presence of Bifidobacterium bifidum and Lactobacillus spp in StoolTwo weeksStool culture/ Gram Stain and quantitative real time PCR were used to for this outcome.

Secondary

MeasureTime frameDescription
CD4 and CD8 concentration in the serum2 weeksSerum concentrations of CD4 and CD8 cytokines were measured by by ELISA
Change in Weight (gram)Baseline and 2 weeksThe difference between weight at enrollment and at 2 weeks was measured for all subjects
Change in crown-heel length (cm)Baseline and 2 weeksThe difference between the length at enrollment and at 2 weeks was measured for all subjects
Change in head circumference (cm)Baseline and 2 weeksThe difference between head circumference at enrollment and at 2 weeks was measured for all subjects

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026